Alternative Drug Delivery Systems

Drug release, absorption, distribution, and elimination profiles to improve product efficacy and safety, as well as patient convenience and compliance, can be modified through drug delivery technologies. Oral and parenteral are the most common routes of drug delivery, but alternative drug delivery is preferred in many situations. SRI Biosciences has expertise in the development of these specialized drug delivery systems:

  • Nasal formulations

  • Vaginal formulations

  • Polymeric films and microspheres

  • Biodegradable implants

  • Transdermal delivery

  • Transmucosal bioadhesive delivery

  • Nanoparticle drug delivery

  • Gels

  • Ointments

  • Creams

SRI has been working on formulation and delivery approaches to enable currently approved drugs to take advantage of more economical and practical drug delivery technology in an approach sometimes referred to as “IV to PO.” We have had great success in reformulating IV drug products into oral dosage forms.

Projects

scientist checking a batch of vaccines
Needle-Free Transmucosal Drug Delivery System

SRI has patented a novel approach to vaccine delivery that is safe for pediatric use, eliminating the need for painful injections.

Topics: Alternative Drug Delivery Systems Drug Formulation Development Medicinal Chemistry Pharmaceutical R+D

Press Releases

Researchers Developing New Multiple Sclerosis Drug That Can Be Taken Orally

Researchers at SRI are developing a new Multiple Sclerosis drug that can be taken by mouth. It will be more convenient than current treatments, which require frequent hospital visits for injections or intravenous infusions.

Topics: Alternative Drug Delivery Systems Drug Formulation Development Drug Pipeline Immunology + Inflammation Medicinal Chemistry Pharmaceutical R+D Pharmaceutical Sciences: Stability Studies Preclinical Drug Development
microscopic view of the HIV virus
SRI International Researchers Developing Bioadhesive Gel to Protect Women from HIV and HSV Infections

Researchers are developing and testing a topical microbicide gel for drug delivery. The innovative formulation will be a combination therapy against human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV-2) infections in women.

Topics: Alternative Drug Delivery Systems Drug Formulation Development Drug Pipeline Infectious Diseases Pharmaceutical R+D Pharmaceutical Sciences: Analytical Chemistry Pharmaceutical Sciences: Stability Studies Preclinical Drug Development

Divisions, Centers + Labs